<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Txt>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312949/suppl/GSE312949_raw_counts_All_Samples.txt.gz</Txt><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312949/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Oryctolagus cuniculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312949</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>CQMUH-011 mitigated LPS-induced acute lung injury in neonatal rabbits</name><description>Background: Neonatal sepsis-associated acute lung injury (ALI) is a therapeutic challenge. This study evaluated the efficacy of CQMUH-011, a novel small-molecule compound, against lipopolysaccharide (LPS)-induced ALI in neonatal rabbits. Methods: Neonatal rabbits at postnatal age 5-7 days were intraperitoneally injected with LPS (50 mg/kg) to induce ALI, and subsequently treated with CQMUH-011 at 675 μg/kg at 0.5 hour. Outcomes within 10-hour of observation were assessed through survival analysis, neurobehavioral assessment, blood gas, histopathological scoring, alveolar phospholipid quantification in bronchoalveolar lavage fluid, RT-PCR for inflammatory mediators and surfactant proteins, and gene expression profiles through transcriptomic analysis. Results: LPS administration induced severe ALI characterized by metabolic acidosis, hypoxemia, lung inflammatory injury, neuromotor dysfunction, and mortality. CQMUH-011 improved neurological deficits, restored blood gas balance, enriched phospholipid pool, reduced lung injury scores, diminished leukocyte infiltration and improved alveolar expansion. RT-PCR results showed significantly mitigated mRNA expressions of proinflammatory cytokines and enhanced surfactant proteins and phospholipid synthesis-associated enzymes. Transcriptomic analysis revealed the dual mechanism of CQMUH-011 by downregulating multiple inflammatory pathways, including cytokine-cytokine receptor interaction, T-helper 17 cell differentiation, interleukin-17 and nuclear transcription factor-kappa B, tumor necrosis factor-α, concurrent with activation of phosphatidylinositol 3-kinase/protein kinase B-dependent cytoprotection, cytoskeletal remodeling, and intercellular junction reinforcement. Conclusions: CQMUH-011 exerts potent anti-inflammatory and lung-protective effects in neonatal ALI by modulating critical inflammatory and repair pathways, making it a promising therapeutic candidate for sepsis-associated ALI.</description><dates><publication>2026/06/18</publication></dates><accession>GSE312949</accession><cross_references><GSM>GSM9357389</GSM><GSM>GSM9357388</GSM><GSM>GSM9357387</GSM><GSM>GSM9357386</GSM><GSM>GSM9357396</GSM><GSM>GSM9357395</GSM><GSM>GSM9357394</GSM><GSM>GSM9357393</GSM><GSM>GSM9357392</GSM><GSM>GSM9357391</GSM><GSM>GSM9357390</GSM><GPL>33967</GPL><GSE>312949</GSE><taxon>Oryctolagus cuniculus</taxon><PMID>[42002599]</PMID></cross_references></HashMap>